ETF-Investor

SYRE Spyre Therapeutics

$97.63-3.77%2026-11-19 · Quote reference; see timestamp

01Recent performance

PeriodReturnHistorical percentile
Daily-3.77%Insufficient history
WTD—Insufficient history
MTD—Insufficient history
Period comparison through 2026-11-19
YTD—
From 52W high—
IV30—

Loading full research…

02How expensive is the company?

TTM PE N/M

Nonpositive earnings: PE percentile is not meaningful

Actual history 2.22Y · 3 month-end samples · 2024-08-30 — 2024-10-31

A comparison with its own history, not a standalone investment decision.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
2024-08-302024-10-31

PB 10.24×

PB 10.24× · 95.00%
0%25%50%75%100%

Actual history 7.64Y · 80 month-end samples · 2019-03-29 — 2026-10-30

PB is affected by buybacks and equity structure; it is not a standalone trade signal.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
2019-03-292026-10-30

03Earnings outlook

Forward PE—
Expected EPS growth—

Forward PE · Futu · 2026-11-01

No verified comparable EPS growth forecast. Growth is not inferred from valuation ratios.

No verified comparable Forward PE history; no percentile scale is shown.

04ETFs holding the company

Loading full research…

05Peers & similar companies

Peers and similar companies first, followed by common stocks where needed.

Watch
ARGX——Similar business————————
CRSP——Similar business————————
IOVA——Similar business————————
MRNA——Similar business————————
RVMD——Similar business————————
AAPL——Common stock————————
NVDA——Common stock————————
MSFT——Common stock————————
GOOGL——Common stock————————
AMZN——Common stock————————

Loading existing stock data…

Percentiles use each company’s own history; actual years appear beside values. Missing data is shown as —. Quote and valuation dates may differ; hover over values for available dates.

06Understand the company

The business in one sentence
Develops treatments for immune-inflammatory and related diseases.

How it earns money
Develops antibody candidates for inflammatory and immune conditions, including inflammatory bowel disease.

Why customers choose it · Research perspective
Candidates must show response, dosing convenience and safety. Combinations need their own evidence.

What to watch next · Research perspective
Watch enrollment, remission data and liquidity to distinguish preliminary signals from evidence for the next stage.

Sources

Spyre Therapeutics · Company filing

Futu · Spyre Therapeutics company profile

Sources checked

For research, not personal investment advice.

PASSWORD-FREE ACCESS

Continue with email

We’ll send you a secure sign-in link. No password required.

By continuing, you agree to the Terms and acknowledge the Privacy Policy.